FDA Tobacco Chief Highlights Progress, Challenges in Product Reviews and Enforcement
Dr. Bret Koplow, acting director of the FDA’s Center for Tobacco <a href="https://shoppixy.com/15-best-products-for-cats-in-2026-reviews-top-picks/” title=”15 Best Products for Cats in 2026 – Reviews & Top Picks”>Products (CTP), participated in a fireside chat to open the second day of the American Tobacco and Nicotine Forum (ATNF) in Leesburg, Va. Christopher Greer, president and CEO of the Nicotine Council, led the discussion, expressing interest in the internal operations of the regulatory agency.
Koplow reported that the agency has achieved substantial progress in reducing its backlog of premarket tobacco applications, having decreased the volume by approximately 70% over the last year and successfully cleared the acceptance queue. He noted that while the FDA has processed roughly 27 million applications, only a limited number have received authorization, primarily because the majority of submissions failed to provide the scientific evidence necessary to prove public health benefits.
The agency is currently focused on enhancing transparency and providing clearer guidance for applicants, including an initiative to share insights gained from the review process to assist companies in meeting regulatory requirements. Koplow also pointed to efforts to refine evaluations for specific product categories, such as nicotine pouches, where a pilot program facilitated quicker authorizations and is expected to help shape future regulatory strategies.
Regarding enforcement, Koplow emphasized the agency’s intensified efforts against illicit goods, which include significant seizures of unauthorized e-cigarettes conducted in partnership with other federal agencies, with the majority of these products arriving from China. He acknowledged the persistent difficulty of balancing harm reduction for adult smokers with the need for youth protection, noting that while youth vaping rates have declined, concerns remain regarding public perception of nicotine risks and the necessity for more robust data on the comparative benefits of alternative products.
